Prime Medicine, Inc.
Close on Oct 19, 2026
- Market cap
- $678.77M
- P/E (TTM)
- –
- Dividend yield
- –
About Prime Medicine
Biological Products, (No Diagnostic Substances), SIC 2836
The company is a biotechnology enterprise that develops genetic medicines using prime editing technology to correct pathogenic mutations without generating double-stranded DNA breaks. Its development pipeline encompasses wholly owned in vivo therapies for genetic liver and lung conditions as well as partnered ex vivo cell therapies. Key product candidates include PM577 for Wilson disease, PM647 for alpha-1 antitrypsin deficiency, an airway program for cystic fibrosis, and PM359 for chronic granulomatous disease. Its target beneficiaries are patients with severe genetic disorders, while its commercial counterparties and collaborators include biopharmaceutical corporations such as Bristol-Myers Squibb and non-profit organizations like the Cystic Fibrosis Foundation.
Regarding scale and geography, the provided text does not disclose the location of the company's corporate headquarters or its facility counts. The entity maintains research, manufacturing, and quality systems supporting preclinical and early-stage clinical operations. Its operations encompass worldwide intellectual property licenses and global commercial agreements, alongside regulatory engagement with authorities in the United States.
Summary of the business section of Prime Medicine's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Prime Medicine, Inc.
- Headquarters
- Cambridge, MA
- Address
- 60 First St. 02141
- Phone
- (617) 465-0013
- Employees
- 146, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- PRME
- Exchange
- Nasdaq
- IPO date
- Oct 21, 2022
- Shares outstanding
- 181M, Jul 31, 2026
- Public float
- $238.76M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1894562
- CUSIP
- 74168J101
- ISIN
- US74168J1016
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Allan Reine | Chief Executive Officer, Director | 125,000 |
| Keith Michael Gottesdiener | See Remarks, Director | 4,361,078 |
| Svetlana Ni Makhni | Chief Financial Officer | – |
| Carman Alenson | See Remarks | – |
| Ann L. Lee | Chief Technical Officer | 100,000 |
| Richard Brudnick | Chief Business Officer | 20,000 |
| Meredith Goldwasser | SVP, Strategy & Corporate Ops. | 176,917 |
| Jeremy Duffield | Chief Scientific Officer | 965,001 |
| Wendy Chung | Director | – |
| Robert Nelsen | Director | 18,502,974 |
| Kaye I. Foster-Cheek | Director | – |
| David P. Schenkein | Director | – |
| Michael Aaron Kelly | Director | – |
| Thomas Cahill | Director | 5,305,679 |
| Jeffrey D. Marrazzo | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 146 full-time employees, of whom 63 have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 21, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 17, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |